Vitronectin Concentrates Proteolytic Activity on the Cell Surface and Extracellular Matrix by Trapping Soluble Urokinase Receptor-Urokinase Complexes
Open Access
- 1 April 1998
- journal article
- Published by American Society of Hematology in Blood
- Vol. 91 (7) , 2305-2312
- https://doi.org/10.1182/blood.v91.7.2305
Abstract
Urokinase-type-plasminogen activator (uPA) and its receptor are localized in the vessel wall where they are involved in cellular activation and remodelling processes. Besides the cell surface glycolipid (GPI)-anchored urokinase receptor (uPAR), which binds uPA with high affinity, recent evidence points to the existence of soluble uPAR (suPAR), as well. In the present study, the origin, binding mechanism, and cellular effects of suPAR were examined. Under basal conditions human vascular smooth muscle cells (HVSMC), human umbilical vein endothelial cells (HUVEC), and monocytic cells released 0.1 to 2 ng/mL suPAR, which was increased twofold to fivefold after phorbol ester (PMA) stimulation, as measured by a function-dependent enzyme-linked immunosorbent assay (ELISA). suPAR alone did not bind to HVSMC or HUVEC, but reduced cellular uPA binding by 50% to 70%. However, after removal of GPI-uPAR with phosphatidylinositol-specific phospholipase C, suPAR dose-dependently increased uPA binding by fourfold to fivefold. This increase in binding was completely inhibited by vitronectin (VN) and by a monoclonal antibody against VN, but not by other matrix proteins or antibodies. Thus, VN-mediated uPA binding to cells was regulated by the ratio of soluble to surface-associated uPAR. In a uPAR-deficient cell line (LM-TK−), suPAR increased uPA binding up to 10-fold, whereas the truncated receptor lacking the amino-terminal uPA-binding domain was ineffective. The formation of a ternary uPA/suPAR/VN-complex on the cell surface and the free extracellular matrix could be inhibited by a monoclonal antibody against VN, as well as by plasminogen activator inhibitor-1 (PAI-1). Moreover, VN-mediated binding of the uPA/suPAR-complex led to a fivefold increase in plasminogen activator activity. Through this novel pathway, VN concentrates the uPA/suPAR-complex to cell surfaces and extracellular matrix sites, leading to the accumulation of plasminogen activator activity required for cell migration and tissue remodelling processes.Keywords
This publication has 45 references indexed in Scilit:
- Contrasting Effects of Plasminogen Activators, Urokinase Receptor, and LDL Receptor–Related Protein on Smooth Muscle Cell Migration and InvasionArteriosclerosis, Thrombosis, and Vascular Biology, 1996
- Integrins as promiscuous signal transduction devicesImmunology Today, 1996
- Thrombin Regulation by Physiological Inhibitors: The Role of VitronectinSeminars in Thrombosis and Hemostasis, 1996
- Plasminogen Activator Expression in Human Atherosclerotic LesionsArteriosclerosis, Thrombosis, and Vascular Biology, 1995
- Migrating Vascular Smooth Muscle Cells Polarize Cell Surface Urokinase Receptors after Injury in VitroExperimental Cell Research, 1995
- Both Pro‐uPA and uPA: PAI‐1 Complex Bind to the α2‐Macroglobulin Receptor/LDL Receptor–Related ProteinAnnals of the New York Academy of Sciences, 1994
- Paroxysmal nocturnal hemoglobinuria and the glycosylphosphatidylinositol anchor.Journal of Clinical Investigation, 1994
- Cytokines induce urokinase-dependent adhesion of human myeloid cells. A regulatory role for plasminogen activator inhibitors.Journal of Clinical Investigation, 1993
- Binding and endocytosis of thrombospondin and thrombospondin fragments in endothelial cell cultures analyzed by cuprolinic blue staining, colloidal gold labeling, and silver enhancement techniques.Journal of Histochemistry & Cytochemistry, 1991
- Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphenylglycolurilBiochemical and Biophysical Research Communications, 1978